**Core Concept**
The question is testing the student's knowledge of pharmacological management of Chronic Obstructive Pulmonary Disease (COPD). The underlying principle is the selection of an appropriate bronchodilator to alleviate symptoms and improve lung function in patients with COPD.

**Why the Correct Answer is Right**
In COPD, the airway obstruction is primarily due to inflammation, mucus hypersecretion, and airway smooth muscle hypertrophy. Long-acting muscarinic antagonists (LAMAs) are effective bronchodilators that specifically target the muscarinic receptors in the airway smooth muscle, leading to relaxation of the muscles and widening of the airways. This results in improved lung function, reduced symptoms, and improved quality of life for patients with COPD.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because short-acting beta-2 agonists (SABAs) are primarily used as rescue medications for acute bronchospasm, rather than as long-term maintenance therapy for COPD.
**Option B:** This option is incorrect because theophylline is a methylxanthine with bronchodilatory properties, but it is not a first-line treatment for COPD due to its narrow therapeutic index and potential for adverse effects.
**Option C:** This option is incorrect because inhaled corticosteroids (ICS) are primarily used in COPD to reduce inflammation, but they are not bronchodilators and do not provide immediate relief from bronchospasm.

**Clinical Pearl / High-Yield Fact**
LAMAs, such as tiotropium, are more effective than LAMA/SABA combinations in improving lung function and reducing exacerbations in patients with COPD.

**Correct Answer: C. Tiotropium**